UCB Expands Immunology Pipeline with Planned Acquisition of Candid Therapeutics and Its Novel T-Cell Engager Platform UCB has taken a significant step forward in its strategic expansion within immunology by…
J&J Highlights FDA Approval of STELARA® for Pediatric Crohn’s Disease The U.S. Food and Drug Administration (FDA) has approved STELARA (ustekinumab) for the treatment of pediatric patients aged two years…
Incyte Secures FDA Approval for Jakafi XR™ (ruxolitinib) Extended-Release Tablets Across Multiple Hematologic Indications Incyte has announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib)…
Orthogon Therapeutics Secures Additional $11M to Advance BK Virus Antiviral Drug Program Orthogon Therapeutics has announced the successful close of an additional $11 million in follow-on financing, bringing the company’s…
Outfront Health Names Dr. Shane Speirs as Chief Medical Officer Outfront Health has announced the appointment of Shane Speirs, MD, MBA, as its new Chief Medical Officer (CMO), a strategic…
E-Scopics Secures FDA Clearance for Enhanced Hepatoscope® Featuring Advanced Elastography and Expanded Liver Disease Management Capabilities, to Be Showcased at DDW 2026 E-Scopics has announced a major advancement in its…
Knoa Pharma Launches as Public Health-Focused Company Aiming to Support Patients and Combat the Opioid Crisis Knoa Pharma LLC has officially launched as a newly established independent organization with a…
Canadian Association of Optometrists Marks Vision Health Month with “GetEyeWise” Digital Awareness Campaign The Canadian Association of Optometrists is once again placing eye health in the national spotlight through its…
Arrowhead Pharmaceuticals Secures TGA Approval for REDEMPLO® (plozasiran) in Australia, Broadening Access for Patients with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has announced a significant regulatory milestone…
Align Technology Authorizes $200 Million Share Buyback Program Align Technology Inc., a global leader in digital orthodontics and restorative dentistry, has announced plans to repurchase $200 million of its common…
Agendia to Showcase New Evidence Supporting Expanded Use of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Congress Agendia Inc., a leader in genomic testing for breast cancer, has…
CorFlow Therapeutics Reports Phase 1 Completion, Initiates Phase 2 Enrollment in MOCA II Trial, Gains EU Approval for REVITALISE RCT, and Expands Clinical Leadership CorFlow Therapeutics AG has announced a…